Having participated in Chinese private equity as GP, LP, advisor, and industry association executive, Jenny Zeng has clear ideas as to what makes a good founder. These are being put into practice at MSA Capital
CDH Investments turned The Better Health Company from a New Zealand-only player into a brand with regional recognition. COVID-19 proved a minor obstacle to an ultimately successful trade sale
US and China-based clinical contract research organization (CRO) company ClinChoice has raised a USD 150m Series E round led by Legend Capital.
Sequoia Capital has hit the hard cap on each of the four funds in its latest China vintage, accumulating USD 8.8bn for deployment in seed through late-growth rounds.
Semi-Tech, a China-based semiconductor manufacturing software provider, has raised CNY 540m (USD 81m) across two rounds - the second extended tranche of a Series A and a Series B.
China-based Enpower Greentech, which claims to be a pioneer in next-generation all-solid-state batteries (ASSBs), has raised more than USD 20m in an extended Series A round led by Sequoia Capital China and Dayone Capital.
Beijing-based Joy Capital has set a lower target for its latest US dollar-denominated fund than in the previous vintage and decided against raising a second accompanying growth vehicle.
CDH Investments has agreed to sell New Zealand-based supplements manufacturer The Better Health Company (TBHC) to Nestlé Health Science for an undisclosed sum.
PE investment in China biotech has collapsed amid failed IPO processes and disputed valuations. Pockets of activity remain, though questions around commercialisation have yet to be answered
Shawya is a fast-rising Chinese direct-to-consumer brand that takes a technology-driven approach to skincare. Welkin Capital is helping it address growing pains around talent and omnichannel capabilities
Paul Yang, KKR’s Greater China head, is moving to an advisory role as the private equity firm looks to appoint a replacement based full-time in mainland China.
Gogox, a last-mile logistics company formed through the merger of Hong Kong's GoGoVan and an affiliate of mainland China-based 58.com, fell 22% on its Hong Kong trading debut following a HKD 771.4 (USD 98.3m) IPO.
Despite headwinds that have afflicted all China-focused managers, FountainVest Partners closed its fourth fund just above target on USD 2.9bn. One-third of the corpus has already been deployed
Therorna, a China-based biotech company specializing in vaccines and drugs based on circular RNA technology, has raised USD 42m in Series A funding.
Asia-focused private equity firm PAG has put its Hong Kong IPO on hold, three sources familiar with the situation told Mergermarket, AVCJ’s sister title.
Axbio, a China-based provider of gene sequencing and diagnostic systems, has raised nearly USD 100m in Series B funding led by AstraZeneca-CICC Healthcare Industrial Fund and Yunfeng Capital.
Temasek Holdings has led a USD 80m Series B round for Shanghai-based bio-manufacturing start-up Mojia Biotech.
Beijing-based HeliXon, an artificial intelligence-enabled developer of protein-based drugs, has raised CNY 500m (USD 75m) in Series A funding led by 5Y Capital. Other investors include Gaorong Capital and Neumann Capital.
US-based private equity firm Platinum Equity has agreed to acquire Hop Lun, a Hong Kong-headquartered producer of fashion lingerie and swimwear that serves a global client base.
Linctex Digital, a Shanghai-based design services platform for the fashion industry, has raised an extended pre-Series B round of nearly USD 100m from GL Ventures and CDH Investments.
Chinese venture capital firm ZWC Partners has reached the first close of CNY 1bn (USD 149m) on its debut renminbi-denominated fund. The overall target is CNY 1.5bn.
Asia’s sparse placement agent scene is fleshing itself out despite macro headwinds, but the model is being revised to adapt to a changing market. This appears irreversible
Zhongchu Guoneng Technology is leading China’s push into compressed air energy storage as a means of harnessing fast-rising yet unstable wind and solar capacity. Tsinghua Holdings Capital is among the backers
US-listed Hywin Holdings is plugging China’s rich into private asset classes one handshake at a time despite increasing digitisation in this wealth migration theme. PE is a fast-growing slice of the pie